ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT
Shows Promise Alone And In Keytruda Combo
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
